Drug Profile


Alternative Names: DP 178; Fuzeon; Pentafuside; R-698; T-20

Latest Information Update: 30 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Duke University; Trimeris
  • Developer Alexion Pharmaceuticals; Trimeris
  • Class Antiretrovirals; Antivirals; Env gene products; Peptide fragments; Viral fusion proteins
  • Mechanism of Action HIV fusion inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 23 Jun 2015 Synageva BioPharma has been acquired by Alexion Pharmaceuticals
  • 02 Nov 2011 Trimeris has merged with Synageva BioPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top